157 related articles for article (PubMed ID: 36894309)
1. A prospective, comparative study of clinical outcomes following clinic-based versus self-use of medical abortion.
Kapp N; Mao B; Menzel J; Eckersberger E; Saphonn V; Rathavy T; Pearson E
BMJ Sex Reprod Health; 2023 Oct; 49(4):300-307. PubMed ID: 36894309
[TBL] [Abstract][Full Text] [Related]
2. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.
Raifman S; Ralph L; Biggs MA; Grossman D
Reprod Health; 2021 May; 18(1):91. PubMed ID: 33947413
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion.
Tamang A; Puri M; Lama K; Shrestha P
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):104-15. PubMed ID: 25702074
[TBL] [Abstract][Full Text] [Related]
4. Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial.
Iyengar K; Paul M; Iyengar SD; Klingberg-Allvin M; Essén B; Bring J; Soni S; Gemzell-Danielsson K
Lancet Glob Health; 2015 Sep; 3(9):e537-45. PubMed ID: 26275330
[TBL] [Abstract][Full Text] [Related]
5. Towards safe abortion access: an exploratory study of medical abortion in Cambodia.
Petitet PH; Ith L; Cockroft M; Delvaux T
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):47-55. PubMed ID: 25702068
[TBL] [Abstract][Full Text] [Related]
6. Self-administered versus provider-administered medical abortion.
Gambir K; Kim C; Necastro KA; Ganatra B; Ngo TD
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013181. PubMed ID: 32150279
[TBL] [Abstract][Full Text] [Related]
7. Medical abortion offered in pharmacy versus clinic-based settings.
Rodriguez MI; Edelman A; Hersh A; Gartoulla P; Henderson J
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD013566. PubMed ID: 34114643
[TBL] [Abstract][Full Text] [Related]
8. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial.
Schaff EA; Fielding SL; Westhoff C; Ellertson C; Eisinger SH; Stadalius LS; Fuller L
JAMA; 2000 Oct; 284(15):1948-53. PubMed ID: 11035891
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks of pregnancy in Kazakhstan.
Platais I; Tsereteli T; Grebennikova G; Lotarevich T; Winikoff B
Int J Gynaecol Obstet; 2016 Sep; 134(3):268-71. PubMed ID: 27352735
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Self-Managed Medication Abortion Between 9 and 16 Weeks of Gestation.
Moseson H; Jayaweera R; Egwuatu I; Grosso B; Kristianingrum IA; Nmezi S; Zurbriggen R; Bercu C; Motana R; Gerdts C
Obstet Gynecol; 2023 Aug; 142(2):330-338. PubMed ID: 37411022
[TBL] [Abstract][Full Text] [Related]
11. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Faucher P; Baunot N; Madelenat P
Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
[TBL] [Abstract][Full Text] [Related]
13. Mailing abortion pills does not delay care: A cohort study comparing mailed to in-person dispensing of abortion medications in the United States.
Koenig LR; Raymond EG; Gold M; Boraas CM; Kaneshiro B; Winikoff B; Coplon L; Upadhyay UD
Contraception; 2023 May; 121():109962. PubMed ID: 36736715
[TBL] [Abstract][Full Text] [Related]
14. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days' LMP: a prospective comparative open-label trial.
Bracken H; Dabash R; Tsertsvadze G; Posohova S; Shah M; Hajri S; Mundle S; Chelli H; Zeramdini D; Tsereteli T; Platais I; Winikoff B
Contraception; 2014 Mar; 89(3):181-6. PubMed ID: 24332431
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
Baird DT; Sukcharoen N; Thong KJ
Hum Reprod; 1995 Jun; 10(6):1521-7. PubMed ID: 7593528
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of assessing the safety and effectiveness of menstrual regulation medications purchased from pharmacies in Bangladesh: a prospective cohort study.
Footman K; Scott R; Taleb F; Dijkerman S; Nuremowla S; Reiss K; Church K
Contraception; 2018 Feb; 97(2):152-159. PubMed ID: 28823841
[TBL] [Abstract][Full Text] [Related]
17. Acceptability and feasibility of medical abortion in Nepal.
Karki C; Pokharel H; Kushwaha A; Manandhar D; Bracken H; Winikoff B
Int J Gynaecol Obstet; 2009 Jul; 106(1):39-42. PubMed ID: 19345944
[TBL] [Abstract][Full Text] [Related]
18. Extending outpatient medical abortion services through 70 days of gestational age.
Winikoff B; Dzuba IG; Chong E; Goldberg AB; Lichtenberg ES; Ball C; Dean G; Sacks D; Crowden WA; Swica Y
Obstet Gynecol; 2012 Nov; 120(5):1070-6. PubMed ID: 23090524
[TBL] [Abstract][Full Text] [Related]
19. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
Guengant JP; Bangou J; Elul B; Ellertson C
Contraception; 1999 Sep; 60(3):167-72. PubMed ID: 10640161
[TBL] [Abstract][Full Text] [Related]
20. Self-managed medication abortion outcomes: results from a prospective pilot study.
Moseson H; Jayaweera R; Raifman S; Keefe-Oates B; Filippa S; Motana R; Egwuatu I; Grosso B; Kristianingrum I; Nmezi S; Zurbriggen R; Gerdts C
Reprod Health; 2020 Oct; 17(1):164. PubMed ID: 33109230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
